Inserm Unit 1138, Team CELLULAR AND CLINICAL PATHOGENESIS OF DIABETES (Team F. Foufelle)
CORDELIERS RESEARCH CENTER, Paris
Tél. : +33 (0)1 44 27 24 67
Mail : email@example.com
Metabolic complications of obesity and overweight, such as type 2 diabetes, are an important challenge to public health. Teams led by Nicolas Venteclef, Dominique Langin, Karine Clément and Irina Udalova (Kennedy Institute of Rheumatology, University of Oxford, UK) in collaboration with several teams, have succeeded in elucidating part of the mechanisms involved in the development of these metabolic complications associated with obesity. Results of these studies are published online in the journal Nature Medicine.
Currently, over one and a half billion people worldwide suffer from overweight or obesity. We have known for about a decade that a chronic state of inflammation is present in obese patients. This state might play a fundamental role in the development of associated metabolic diseases. This inflammation results from abnormal activity of the immune system observed both systemically (bloodstream) and locally (in metabolic organs such as the liver, muscles, pancreas and especially the adipose tissue).
Following excessive weight gain, the adipose tissue develops in an abnormal manner in the intra-abdominal region (android obesity), and becomes an important source of pro-inflammatory mediators, the “chemical messengers” that activate inflammation, with harmful metabolic consequences. This phenomenon is particularly provoked by the accumulation of pro-inflammatory macrophages in this tissue. Paradoxically, some obese subjects do not develop metabolic alterations. Indeed, when adipose tissue expansion occurs in the more superficial deposits, such as the subcutaneous adipose tissue (gynoid obesity), the risk of developing metabolic complications is reduced.
In an earlier study (Dalmas et al. Diabetes 2014), the team led by Karine Clément (Guerre-Millo and coll., UMR_S 1166, Paris, France), in collaboration with Nicolas Venteclef, had observed the importance of inflammatory and prodiabetogenic cross-talk between macrophages and lymphocytes in the visceral adipose tissue of obese patients.
Influence of IRF5 on the nature of adipose tissue in obese patients and its metabolic consequences ©Inserm/N. Venteclef (viscAT: visceral adipose tissue. scAT: subcutaneous adipose tissue)Data obtained with mice were confirmed in overweight, obese or massively obese patients, by showing significant correlation between IRF5 expression in the visceral adipose tissue and metabolic dysfunctions associated with obesity.
This pioneering study suggests that the immune system (in this case the macrophages of the adipose tissue) directly influences the accumulation of fatty matter in the visceral region, a likely target in the prevention of type 2 diabetes. For the researchers, “It is therefore crucial to decipher the different aspects of inflammation in order to better understand the multifactorial diseases associated with obesity, such as type 2 diabetes.”
The approach implemented in this study encapsulates translational research, which is aimed at developing effective therapies for patients by establishing a fruitful dialogue between clinicians and researchers, in order to produce robust results that are supported by mouse models while being relevant to humans.
This work received financial support from the French National Research Agency (ANR), Inserm, Pierre and Marie Curie University (UPMC), the French Medical Research Foundation (FRM), ICAN and the Ile de France Region (CORDDIM).
Type 2 diabetes is a risk factor for the development of a severe form of Covid-19. Identifying the immune- and inflammatory markers associated with these severe forms of the disease in this patient population would enable earlier and more appropriate care. ...
Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity
Elise Dalmas1,2,13, Amine Toubal1–3,13, Fawaz Alzaid2,3,13, Katrina Blazek4, Hayley L Eames4, Kristell Lebozec2,3, Maria Pini1,2, Isabelle Hainault2,3, Emilie Montastier5–7, Raphaël G P Denis8, Patricia Ancel1,2, Amélie Lacombe2, Yin Ling1,2, Omran Allatif1,2, Céline Cruciani-Guglielmacci8, Sébastien André1,2, Nathalie Viguerie6,7, Christine Poitou1,2,9, Vladimir Stich10,11, Alexandra Torcivia12, Fabienne Foufelle2,3, Serge Luquet8, Judith Aron-Wisnewsky1,2,9, Dominique Langin9,10, Karine Clément1,2,9, Irina A Udalova4 & Nicolas Venteclef 2,3
1 Sorbonne Universités, Université Pierre et Marie-Curie; INSERM UMR_S 1166-ICAN, Nutriomics, Paris, France.
2 Institute of Cardiometabolism and Nutrition, Paris, France.
3 Sorbonne Universités, Université Pierre et Marie-Curie, INSERM, UMR_S 1138 Cordeliers Research, Paris, France.
4 Kennedy Institute Trust of Rheumatology, University of Oxford, Oxford, UK.
5 INSERM, University of Toulouse, Paul Sabatier University, UMR 1048, Toulouse, France.
6 Department of Clinical Biochemistry, Toulouse University Hospitals, Toulouse, France.
7 Department of Nutrition, Toulouse University Hospitals, Toulouse, France.
8 Université Paris Diderot, Sorbonne Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR 8251, Paris, France.
9 Heart and Metabolism Division, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
10 Department of Sports Medicine, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
11 Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
12 Visceral Surgery Division, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
13 These authors contributed equally to this work.
Nature Medicine, 4 mai 2015